Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors-Reference-Cited by-同舟云学术

Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors

Published:2004-01 Issue:1 Volume:15 Page:161-171
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Vera K.,Djafari L.,Faivre S.,Guillamo J.-S.,Djazouli K.,Osorio M.,Parker F.,Cioloca C.,Abdulkarim B.,Armand J.-P.,Raymond E.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/15/1/161/332069/mdh003.pdf

Reference41 articles.

1. Activity of temozolomide against human tumor colony-forming units;Raymond;Clin Cancer Res,1997

2. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methylimidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045: M&B39831), a novel drug with potential as an alternative to dacarbazine;Stevens;Cancer Res,1987

3. Temozolomide and treatment of malignant glioma;Friedman;Clin Cancer Res,2000

4. Multifaceted resistance of gliomas to temozolomide;Bocangel;Clin Cancer Res,2002

5. Pharmacologic disruption of base excision repair sensitises mismatch repair-deficient and -proficient colon cancer cells to methylating agents;Liu;Clin Cancer Res,1999

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Central Nervous System;Side Effects of Cancer Therapy;2023

2. Polymeric nanoparticles for drug delivery in glioblastoma: State of the art and future perspectives;Journal of Controlled Release;2022-09

3. Nek1-inhibitor and temozolomide-loaded microfibers as a co-therapy strategy for glioblastoma treatment;International Journal of Pharmaceutics;2022-04

4. Oncological management of advanced neuroendocrine tumours (Review);Molecular and Clinical Oncology;2020-06-25

5. Central Nervous System;Side Effects of Medical Cancer Therapy;2018